Search

Your search keyword '"Dubin, G"' showing total 354 results
Start Over Author "Dubin, G"
354 results on '"Dubin, G"'

8. Structure of nsp14 from SARS-CoV-2 in complex with SAH

Author

Czarna, A., primary, Plewka, J., additional, Kresik, L., additional, Matsuda, A., additional, Abdulkarim, K., additional, Robinson, C., additional, OByrne, S., additional, Cunningham, F., additional, Georgiou, I., additional, Pachota, M., additional, Popowicz, G.M., additional, Wyatt, P.G., additional, Dubin, G., additional, and Pyrc, K., additional

Published
2022
Full Text
View/download PDF

12. The Role of Herpes Simplex Virus Glycoproteins in Immune Evasion

Author

Dubin, G., Fishman, N. O., Eisenberg, R. J., Cohen, G. H., Friedman, H. M., Compans, R. W., editor, Cooper, M., editor, Koprowski, H., editor, McConnell, I., editor, Melchers, F., editor, Nussenzweig, V., editor, Oldstone, M., editor, Olsnes, S., editor, Potter, M., editor, Saedler, H., editor, Vogt, P. K., editor, Wagner, H., editor, Wilson, I., editor, and Rouse, Barry T., editor

Published
1992
Full Text
View/download PDF

14. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Author

Paavonen, J, Naud, P, Salmerón, J, Wheeler, CM, Chow, S-N, Apter, D, Kitchener, H, Castellsague, X, Teixeira, JC, Skinner, SR, Hedrick, J, Jaisamrarn, U, Limson, G, Garland, S, Szarewski, A, Romanowski, B, Aoki, FY, Schwarz, TF, Poppe, WAJ, Bosch, FX, Jenkins, D, Hardt, K, Zahaf, T, Descamps, D, Struyf, F, Lehtinen, M, and Dubin, G

Published
2009
Full Text
View/download PDF

19. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV-16/18

Author

Szarewski, A., Poppe, W. A.J., Skinner, S. R., Wheeler, C. M., Paavonen, J., Naud, P., Salmeron, J., Chow, S.-N., Apter, D., Kitchener, H., Castellsagué, X., Teixeira, J. C., Hedrick, J., Jaisamrarn, U., Limson, G., Garland, S., Romanowski, B., Aoki, F. Y., Schwarz, T. F., Bosch, F. X., Harper, D. M., Hardt, K., Zahaf, T., Descamps, D., Struyf, F., Lehtinen, M., and Dubin, G.

Published
2012
Full Text
View/download PDF

22. High resolution crystal structure of N-terminal domain of PEX14 from Trypanosoma brucei in complex with the fist compound with sub-micromolar trypanocidal activity

Author

Napolitano, V., primary, Dawidowski, M., additional, Kalel, V.C., additional, Fino, R., additional, Emmanouilidis, L., additional, Lenhart, D., additional, Ostertag, M., additional, Kaiser, M., additional, Kolonko, M., additional, Schilebs, W., additional, Maser, P., additional, Tetko, I., additional, Hadian, K., additional, Plettenburg, O., additional, Erdmann, R., additional, Sattler, M., additional, Popowicz, G.M., additional, and Dubin, G., additional

Published
2020
Full Text
View/download PDF

23. Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodies

Author

Rosillon, D, Baril, L, Del Rosario-Raymundo, MR, Wheeler, CM, Skinner, SR, Garland, SM, Salmeron, J, Lazcano-Ponce, E, Vallejos, CS, Stoney, T, ter Harmsel, B, Lim, TYK, Quek, SC, Minkina, G, McNeill, SA, Bouchard, C, Fong, KL, Money, D, Ilancheran, A, Savicheva, A, Cruickshank, M, Chatterjee, A, Fiander, A, Martens, M, Bozonnat, MC, Struyf, F, Dubin, G, Castellsague, X, Rosillon, D, Baril, L, Del Rosario-Raymundo, MR, Wheeler, CM, Skinner, SR, Garland, SM, Salmeron, J, Lazcano-Ponce, E, Vallejos, CS, Stoney, T, ter Harmsel, B, Lim, TYK, Quek, SC, Minkina, G, McNeill, SA, Bouchard, C, Fong, KL, Money, D, Ilancheran, A, Savicheva, A, Cruickshank, M, Chatterjee, A, Fiander, A, Martens, M, Bozonnat, MC, Struyf, F, Dubin, G, and Castellsague, X

Abstract

BACKGROUND: Infections with human papillomavirus (HPV) types 16 and 18 account for ~70% of invasive cervical cancers but the degree of protection from naturally acquired anti-HPV antibodies is uncertain. We examined the risk of HPV infections as defined by HPV DNA detection and cervical abnormalities among women >25 years in the Human Papilloma VIrus Vaccine Immunogenicity ANd Efficacy trial's (VIVIANE, NCT00294047) control arm. METHODS: Serum anti-HPV-16/18 antibodies were determined at baseline and every 12 months in baseline DNA-negative women (N = 2687 for HPV-16 and 2705 for HPV-18) by enzyme-linked immunosorbent assay (ELISA) from blood samples. HPV infections were identified by polymerase chain reaction (PCR) every 6-months, and cervical abnormalities were confirmed by cytology every 12 months. Data were collected over a 7-year period. The association between the risk of type-specific infection and cervical abnormalities and serostatus was assessed using Cox proportional hazard models. RESULTS: Risk of newly detected HPV-16-associated 6-month persistent infections (PI) (hazard ratio [HR] = 0.56 [95%CI:0.32; 0.99]) and atypical squamous cells of undetermined significance (ASC-US+) (HR = 0.28 [0.12; 0.67]) were significantly lower in baseline seropositive vs baseline seronegative women. HPV-16-associated incident infections (HR = 0.81 [0.56; 1.16]) and 12-month PI (HR = 0.53 [0.24; 1.16]) showed the same trend. A similar trend of lower risk was observed in HPV-18-seropositive vs -seronegative women (HR = 0.95 [0.59; 1.51] for IIs, HR = 0.43 [0.16; 1.13] for 6-month PIs, HR = 0.31 [0.07; 1.36] for 12-month PIs, and HR = 0.61 [0.23; 1.61] for ASC-US+). CONCLUSIONS: Naturally acquired anti-HPV-16 antibodies were associated with a decreased risk of subsequent infection and cervical abnormalities in women >25 years. This possible protection was lower than that previously reported in 15- to 25-year-old women.

Published
2019

43. Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study

Author

Skinner, SR, Wheeler, CM, Romanowski, B, Castellsague, X, Lazcano-Ponce, E, Rowena Del Rosario-Raymundo, M, Vallejos, C, Minkina, G, Da Silva, DP, McNeil, S, Prilepskaya, V, Gogotadze, I, Money, D, Garland, SM, Romanenko, V, Harper, DM, Levin, MJ, Chatterjee, A, Geeraerts, B, Struyf, F, Dubin, G, Bozonnat, M-C, Rosillon, D, Baril, L, Skinner, SR, Wheeler, CM, Romanowski, B, Castellsague, X, Lazcano-Ponce, E, Rowena Del Rosario-Raymundo, M, Vallejos, C, Minkina, G, Da Silva, DP, McNeil, S, Prilepskaya, V, Gogotadze, I, Money, D, Garland, SM, Romanenko, V, Harper, DM, Levin, MJ, Chatterjee, A, Geeraerts, B, Struyf, F, Dubin, G, Bozonnat, M-C, Rosillon, D, and Baril, L

Abstract

The control arm of the phase III VIVIANE (Human PapillomaVIrus: Vaccine Immunogenicity ANd Efficacy; NCT00294047) study in women >25 years was studied to assess risk of progression from cervical HPV infection to detectable cervical intraepithelial neoplasia (CIN). The risk of detecting CIN associated with the same HPV type as the reference infection was analysed using Kaplan-Meier and multivariable Cox models. Infections were categorised depending upon persistence as 6-month persistent infection (6MPI) or infection of any duration. The 4-year interim analysis included 2,838 women, of whom 1,073 (37.8%) experienced 2,615 infections of any duration and 708 (24.9%) experienced 1,130 6MPIs. Infection with oncogenic HPV types significantly increased the risk of detecting CIN grade 2 or greater (CIN2+) versus non-oncogenic types. For 6MPI, the highest risk was associated with HPV-33 (hazard ratio [HR]: 31.9 [8.3-122.2, p < 0.0001]). The next highest risk was with HPV-16 (21.1 [6.3-70.0], p < 0.0001). Similar findings were seen for infections of any duration. Significant risk was also observed for HPV-18, HPV-31, and HPV-45. Concomitant HPV infection or CIN grade 1 or greater associated with a different oncogenic HPV type increased risk. Most women (79.3%) with an HPV infection at baseline cleared detectable infections of any duration, and 69.9% cleared a 6MPI. The risk of progression of HPV infection to CIN2+ in women >25 years in this study was similar to that in women 15-25 years in PATRICIA.

Published
2016

44. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial

Author

Garland, SM, Paavonen, J, Jaisamrarn, U, Naud, P, Salmeron, J, Chow, S-N, Apter, D, Castellsague, X, Teixeira, JC, Skinner, SR, Hedrick, J, Limson, G, Schwarz, TF, Poppe, WAJ, Xavier Bosch, F, de Carvalho, NS, Germar, MJV, Peters, K, Rowena Del Rosario-Raymundo, M, Catteau, G, Descamps, D, Struyf, F, Lehtinen, M, Dubin, G, Garland, SM, Paavonen, J, Jaisamrarn, U, Naud, P, Salmeron, J, Chow, S-N, Apter, D, Castellsague, X, Teixeira, JC, Skinner, SR, Hedrick, J, Limson, G, Schwarz, TF, Poppe, WAJ, Xavier Bosch, F, de Carvalho, NS, Germar, MJV, Peters, K, Rowena Del Rosario-Raymundo, M, Catteau, G, Descamps, D, Struyf, F, Lehtinen, M, and Dubin, G

Abstract

We evaluated the efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in preventing HPV-related disease after surgery for cervical lesions in a post-hoc analysis of the PApilloma TRIal against Cancer In young Adults (PATRICIA; NCT00122681). Healthy women aged 15-25 years were randomized (1:1) to receive vaccine or control at months 0, 1 and 6 and followed for 4 years. Women were enrolled regardless of their baseline HPV DNA status, HPV-16/18 serostatus, or cytology, but excluded if they had previous or planned colposcopy. The primary and secondary endpoints of PATRICIA have been reported previously; the present post-hoc analysis evaluated efficacy in a subset of women who underwent an excisional procedure for cervical lesions after vaccination. The main outcome was the incidence of subsequent HPV-related cervical intraepithelial neoplasia grade 2 or greater (CIN2+) 60 days or more post-surgery. Other outcomes included the incidence of HPV-related CIN1+, and vulvar or vaginal intraepithelial neoplasia (VIN/VaIN) 60 days or more post-surgery. Of the total vaccinated cohort of 18,644 women (vaccine = 9,319; control = 9,325), 454 (vaccine = 190, control = 264) underwent an excisional procedure during the trial. Efficacy 60 days or more post-surgery for a first lesion, irrespective of HPV DNA results, was 88.2% (95% CI: 14.8, 99.7) against CIN2+ and 42.6% (-21.1, 74.1) against CIN1+. No VIN was reported and one woman in each group had VaIN2+ 60 days or more post-surgery. Women who undergo surgical therapy for cervical lesions after vaccination with the HPV-16/18 vaccine may continue to benefit from vaccination, with a reduced risk of developing subsequent CIN2+.

Published
2016

47. HtrA2 protease mutant V226K

Author

Golik, P., primary, Dubin, G., additional, Zurawa-Janicka, D., additional, Lipinska, B., additional, Jarzab, M., additional, Wenta, T., additional, Gieldon, A., additional, and Ciarkowski, A., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results